Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources

August 16, 2023

Discovery of KT-474, a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases

American Chemical Society (ACS) Fall 2023 Meeting
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
May 18, 2023

Safety and Efficacy of IRAK4 Degrater KT-474 (SAR444656) for Hidradenitis Suppurativa and Atopic Dermatitis

European Academy of Dermatology & Venereology (EADV) Symposium 2023
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
October 26, 2022

The Phase 1 Healthy Volunteer Clinical Trial of KT-474

5th Annual Targeted Protein Degradation (TPD) Summit
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
October 26, 2022

Development and Performance of Pharmacodynamic Assays to Demonstrate Proof-of-Mechanism for IRAK4 Degraders in a Phase1 Study

5th Annual Targeted Protein Degradation (TPD) Summit
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
July 28, 2022

Utilizing degraders to Modulate B & T Cell Targets for Autoimmune Diseases

3rd B&T Cell-Mediated Autoimmune Disease Drug Development
Read More
May 31, 2022

STAT3 degraders inhibit Th17 development and cytokine production resulting in profound inhibition of collagen-induced autoimmune murine arthritis

European Alliance of Associations for Rheumatology (EULAR) 2022 Annual Congress
Read More
May 17, 2022

Kinetics of IRAK4 Degradation and Impact on Functional Response in Circulating Immune Cells and Skin Cell Subsets

Society for Investigative Dermatology (SID) 2022 Annual Meeting
Read More
May 3, 2022

STAT3 Degraders Inhibit Cellular Activation, Cytokine Production, and Th17 Development, Resulting in Profound Inhibition of Autoimmunity in the MOG-EAE Model of CNS Inflammation

The American Association of Immunologists (AAI) Immunology2022(TM)
Read More
May 3, 2022

Selective IRAK4 Degradation, Not Kinase Inhibition, Blocks TLR-activated NF-kB and p38 Signaling Leading to broad Cytokine Inhibition

The American Association of Immunologists (AAI) Immunology2022(TM)
Read More
October 28, 2021

Considerations for E3 Ligase Pairing and Screening of Immune-Inflammation Targets

4th Annual TPD Summit
Read More